Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Fortune III who wrote (1409)	7/7/1998 12:47:00 PM
From: Jeffrey L. Henken	Read Replies (1) \| Respond to of 2887

You're welcome Bill. It is a lot of work to put something like that together and I can only hope that one day soon we see ABMI's share price begin to reflect my optimism for the future of the company. Today I found a new press release from "The Online Investor" outlining some prospects for the heavy weights in this industry with a tilt towards BSX: fnews.yahoo.com The following is part of the article: The fast-growing coronary stent market is highly competitive, though, populated with heavyweight competitors like Johnson & Johnson (NYSE:JNJ - news) , Guidant (NYSE:GDT - news) , and this year's hot newcomer Arterial Vascular (Nasdaq:AVEI - news) . This competition is expected to pressure margins, but since Boston Scientific is the one with the latest and greatest product it should enjoy better pricing leverage. It is also the case that BSX has a diverse lineup of vascular and non-vascular products beyond stents, including balloon catheters, grafts and other products used in minimally-invasive surgery. Last month BSX bolstered its balloon catheter business by purchasing the Schneider unit from Pfizer. Schneider brings with it about $350 million in sales and key patents on rapid-exchange balloons. This acquisition combined with the anticipated launch of the Nir stent is expected to vault Boston Scientific into the leading position for the minimally-invasive vascular products market. In my opinion the BSX purchase of Schneider was very important to the future of American BioMed. Competition in this industry is really heating up but there are still plenty of dollars to yet be earned. The biggest and best of these company's will have to continue to broaden their product lines either through internal efforts or more likely through acquisitions. ABMI has 27 patents, some exciting products in R&D and is up for sale to the highest bidder. The stock price may not reflect that today but anyone who thinks ABMI will not head north again this year needs to have their head examined. Regards, Jeff